Barthel Henryk, Hermann Wieland, Kluge Regine, Hesse Swen, Collingridge David R, Wagner Armin, Sabri Osama
Department of Nuclear Medicine, University of Leipzig, Germany.
AJNR Am J Neuroradiol. 2003 Feb;24(2):234-8.
Although previous brain imaging studies of Wilson disease (WD) focused on the dopaminergic system, correlational data on the integrity of the pre- and postsynaptic compartments are lacking. The present study was initiated to intra-individually determine the integrity of these compartments in patients with WD.
A total of 46 patients with WD and 10 matched control subjects underwent [(123)I]2beta-carbomethoxy-3beta-(4[(123)I]iodophenyl)tropane ([(123)I]beta-CIT) and [(123)I]iodobenzamide ([(123)I]IBZM) single photon emission CT (SPECT). For both radiotracers, specific striatal binding ratios (with the cerebellum as the reference region) were calculated after a standardized region-of-interest technique was applied. In addition, the severity of putative neurologic symptoms was evaluated by using a linear scoring system.
In patients without neurologic symptoms, striatal binding ratios of both radiotracers did not differ from those of the control group (13.8 +/- 3.1 vs 12.0 +/- 3.4 and 2.00 +/- 0.19 vs 1.90 +/- 0.27; n.s.). In symptomatic patients, however, striatal binding ratios for both [(123)I]beta-CIT and [(123)I]IBZM were significantly reduced (9.1 +/- 2.3 and 1.64 +/- 0.18; P <.001). In all patients with WD, the [(123)I]beta-CIT and [(123)I]IBZM binding ratios were significantly correlated (r = 0.65, P <.001), as were SPECT parameters and the severity of the neurologic symptoms (r = -0.60 and -0.62; P <.001).
These findings of a concordant bicompartmental dopaminergic deficit in neurologic WD provide in vivo evidence for assigning WD to the group of secondary Parkinsonian syndromes. These results could be relevant in therapeutic decision making in patients with this copper deposition disorder.
尽管先前关于威尔逊病(WD)的脑成像研究聚焦于多巴胺能系统,但缺乏关于突触前和突触后区室完整性的相关数据。本研究旨在个体内确定WD患者这些区室的完整性。
46例WD患者和10例匹配的对照受试者接受了[(123)I]2β-甲氧基羰基-3β-(4[(123)I]碘苯基)托烷([(123)I]β-CIT)和[(123)I]碘苄胺([(123)I]IBZM)单光子发射计算机断层扫描(SPECT)。对于这两种放射性示踪剂,在应用标准化感兴趣区技术后计算纹状体特异性结合率(以小脑作为参考区域)。此外,使用线性评分系统评估假定神经症状的严重程度。
在无神经症状的患者中,两种放射性示踪剂的纹状体结合率与对照组无差异(分别为13.8±3.1对12.0±3.4和2.00±0.19对1.90±0.27;无显著性差异)。然而,在有症状的患者中,[(123)I]β-CIT和[(123)I]IBZM的纹状体结合率均显著降低(分别为9.1±2.3和1.64±0.18;P<.001)。在所有WD患者中,[(123)I]β-CIT和[(123)I]IBZM结合率显著相关(r = 0.65,P<.001),SPECT参数与神经症状严重程度也显著相关(r = -0.60和-0.62;P<.001)。
神经型WD中双区室多巴胺能缺陷一致的这些发现为将WD归为继发性帕金森综合征组提供了体内证据。这些结果可能与这种铜沉积疾病患者的治疗决策相关。